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ABSTRACT
Purpose To evaluate using cationic polymeric nanoparticles
that interact with hyaluronate to form ionically cross-linked
hydrogels to increase the intra-articular retention time of
osteoarthritis drugs in the synovial cavity.
Methods In vitro tests included nanoparticle release from
cross-linked hydrogels using syringe and membrane dissolution
tests, viscosity measurement of synovial fluid containing hydro-
gels, and release-rate measurement for a model active conju-
gated to a cationically substituted dextran using a hydrolyzable
ester linkage in a sink dissolution test. Nanoparticle retention
after intra-articular injection into rat knees was measured in vivo
using fluorescence molecular tomography.
Results Diffusional and convective transport of cationic nanopar-
ticles from ionically cross-linked hydrogels formed in synovial fluid
was slower in vitro than for uncharged nanoparticles. Hydrogels
formed after the nanoparticles were mixed with synovial fluid did
not appreciably alter the viscosity of the synovial fluid in vitro. In vitro
release of a conjugated peptide from the cationic nanoparticles was
approximately 20% per week. After intra-articular injection in rat
knees, 70% of the nanoparticles were retained in the joint for 1 week.
Conclusions This study demonstrates the feasibility of using cat-
ionic polymeric nanoparticles to increase the retention of thera-
peutic agents in articular joints for indications such as osteoarthritis.
KEY WORDS cross-linked hydrogels . increased retention .
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ABBREVIATIONS
ACN acetonitrile
D10P dextran 10 propionate
D10PS dextran 10 propionate succinate
D20AQA-TR dextran 20 acetate quaternary amine-Texas Red
D20P dextran 20 propionate
Dextran 10 dextran with a molecular weight of 10 kDa
Dextran 20 dextran with a molecular weight of 20 kDa
DLS dynamic light scattering
DMOADs disease-modifying osteoarthritis drugs
ELPs elastin-like polypeptides
FITC fluorescein isothiocyanate
FMT fluorescence molecular tomography
HPLC high-performance liquid chromatography
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INTRODUCTION
With an aging U.S. population, the prevalence of
arthritis is expected to increase in the coming decades.
By the year 2030, an estimated 67 million adults aged
18 years and older (25% of the projected total adult
population) will have doctor-diagnosed arthritis, compared
with the approximately 43 million diagnosed adults in 2002.
Two-thirds of those with arthritis will be women. By 2030, an
estimated 25 million adults (9.3%) will report arthritis-
attributable activity limitations. These estimates may be con-
servative, because they do not account for the current trends
in obesity, which may contribute to future cases of osteoar-
thritis (OA) (1).
Currently, medical management of OA, the most prev-
alent form of arthritis, focuses on control of symptoms,
particularly of pain. Management of mild to moderate
OA pain can be accomplished using nonsteroidal anti-
inflammatory drugs (NSAIDs), with COX-2 inhibitors tak-
ing a significant market share from older members of this
class.
Several new classes of molecules have been discov-
ered that inhibit one or more OA pathophysiological
processes. Recent preclinical studies have demonstrated
that these potentially disease-modifying osteoarthritis
drugs (DMOADs) can block specific key disease mecha-
nisms and retard the progression of structural changes
in animal models of OA (2,3). While promising targets
for the development of DMOADs have been identified,
therapeutic agents that target these proteins are often
not suitable for systemic administration, frequently due
to toxicity associated with the target protein, especially
in the context of chronic treatment.
Because the goal is to modulate these targets primarily in
the affected joint, intra-articular administration of com-
pounds is an attractive treatment modality. Intra-articular
administration of a DMOAD directly into the affected joint
offers several advantages over oral dosing; for example, it
can be used for compounds that are poorly absorbed, have
undesirable systemic pharmacokinetic (PK) profiles, or have
systemic toxicity.
Since most agents are rapidly cleared from the joint
after intra-articular injection, the biggest challenge in
the development of intra–articular DMOADs is to
increase retention time of the therapeutic agent in the
joint. For example, the half life of NSAIDs has been
reported to be as short as 1 to 5 h after local injection
(4). This short duration of action requires frequent
injections, which in turn results in expensive treatment,
poor patient compliance, and injection-associated com-
plications (e.g., infection, post-injection flare, crystal-
induced synovitis, cutaneous atrophy) (5).
Many types of particulate carriers have been investigated
for increasing the retention time of therapeutic agents within
the knee cavity, including the following:
& liposomes (6–11);
& microparticles of poly(lactide) (PLA), poly-L-lactide acid
(PLLA), and poly(lactide-co-glycolide) (PLGA), including
hyaluronate-functionalized PLA/PLGA (12–18);
& albumin microparticles (19,20);
& chitosan (21);
& magnetic nanoparticles (22,23);
& solid lipid nanoparticles (24);
& thermally responsive elastin-like polypeptides (ELPs)
(25);
& pH-sensitive gels (26); and
& nanoparticles targeted to the cartilage using phage
display peptides (27).
Some investigators have reported lower systemic expo-
sure with such approaches. For example, Liang et al. showed
that PLLA microspheres decreased systemic exposure 7- to
10-fold compared with free drug after intra-articular injec-
tion in the knees of rabbits (28). However, the intra-articular
retention times for therapeutic agents with these approaches
is still too short for maximum therapeutic effect or the
approaches are subject to other limitations (e.g., they are
applicable only to a narrow range of active compounds or
involve the use of materials with unverified safety profiles).
Thus, although a number of approaches have been studied,
the challenge remains for achieving prolonged retention
with a platform that is amenable to local delivery to the
joint, has high drug loading capacity, and has a good safety
profile.
In this paper, we report the use of cationic polymeric
nanoparticles that form diffuse ionically associated filamen-
tous structures (“ionically cross-linked hydrogels”) with res-
ident hyaluronate in the synovial cavity after intra-articular
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injection (Fig. 1). These nanoparticles were shown to increase
the retention time in the knee of a small fluorescent peptide
cargo (as a drug mimic) that was covalently bound to the
polymeric nanoparticle via a hydrolyzable ester linkage.
MATERIALS AND METHODS
Materials
Ethyl cellulose (Ethocel® Viscosity 4) was a generous gift from
Dow Chemical Co. (Midland, MI). Eudragit RL100 was a
generous gift from Evonik Industries (Essen, Germany).
Poly[2-methoxy-b-(2-ethylhexyloxy)-1,4-phenylenevinylene]
(MEH-PPV) (Product No. 541435) was purchased from Sigma
Aldrich Corp. (St. Louis, MO). Polycaprolactone-b-co-polye-
thyleneoxide (PCL-PEO, Product No. P3128EOCL, 10-kDa
PCL, 5-kDa PEO) was purchased from Polymer Source Inc.
(Montreal, Quebec, Canada). VivoTag® 680 (Product No.
10120) was purchased from VisEn Medical Inc. (Woburn,
MA). The lyophilized potassium salt of hyaluronic acid (“hya-
luronate,” Product No. 53730) from human umbilical cord
was purchased from Fluka (St. Louis, MO). Human synovial
fluid from OA patients (Part No. HYSYNOV-OA) was pur-
chased from Bioreclamation Inc. (Hicksville, NY). A tetrapep-
tide labeled with fluorescein isothiocyanate (FITC) was
provided by Pfizer Inc. (St. Louis, MO). RFK peptide labeled
with fluorescein isothiocyanate (RFK-FITC) was purchased
from American Peptide Company, Inc. (Sunnyvale, CA).
Phosphate buffered saline (PBS “10X,” Product No.
AM9624) for in vitro hydrolysis testing was obtained from
Invitrogen/Life Technologies (Carlsbad, CA).
Syringe filters (1-μm glass-microfiber membrane and 0.2-
μm polyethersulfone [PES] Supor filters) were purchased
from Pall Corp. (Port Washington, NY). Methylene chloride
(Product No. BDH1113) was purchased from VWR Inter-
national LLC (Radnor, PA). Porous polypropylene mem-
branes (Accurel® PP 1E R/P) were purchased from
Membrana GmbH (Wuppertal, Germany).
The detailed synthesis of the following dextran deriva-
tives used in the studies, made by derivatization of either
10-kDa dextran (Dextran 10) or 20-kDa dextran (Dextran
20), will be described in a separate publication:
& Dextran 10 propionate succinate (D10PS)-RFK-FITC;
& Dextran 20 acetate quaternary amine-Texas Red
(D20AQA-TR);
& Dextran 20 propionate (D20P)-VivoTag; and
& Dextran 10 propionate (D10P).












Ionically crosslinked network (“gel”) of nanoparticles and 







Drug or fluorophore 
(conjugated via ester 
bond to core polymer)
~100 nm
Injected Endogenous
Fig. 1 Nanoparticle architecture and mechanism of retention.
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Methods
Nanoparticle Manufacture
The nanoparticles are comprised of two polymers: a
neutral (i.e., uncharged) core polymer and a cationic
surface polymer that interacts with the resident hyalur-
onate in the joint to form ionically associated or “cross-
linked” structures (Fig. 1).
A number of nanoparticle formulations were manufac-
tured to demonstrate the in vitro and in vivo capabilities of the
platform. Eudragit RL100 at 20- to 25-wt.% loading was
used as a model cationic surface polymer for all studies, with
the exception of one in vivo imaging test in which a cationic
dextran was used to show the flexibility in choice of a surface
polymer to associate with hyaluronate. The neutral poly-
mer, which was expected to have less influence on the nano-
particle interaction with hyaluronate, was varied for
different tests for convenience or for optimal incorporation
of model actives. For in vitro imaging tests, formulations
incorporating a polymeric fluorescent dye were used to
visualize the ionically cross-linked structures that were
formed. Nanoparticles made with both Eudragit RL100
and cationically substituted dextran (29) were imaged after
mixing with human OA synovial fluid to demonstrate the
flexibility of using various chemistries to form ionically cross-
linked structures. Uncharged nanoparticles made with PCL-
PEO were used as controls to compare with the cationic
nanoparticles. For the in vitro hydrolysis experiments and the
in vivo test, a small-molecule dye was covalently conjugated
via an ester group to a hydrophobically substituted dextran
“core” polymer to mimic the likely performance of an ester-
linked drug molecule. The nanoparticle compositions are
summarized in Table I and described below.
D20AQA-TR nanoparticles were prepared for fluores-
cence imaging by dissolving 30 mg of D20QA-TR in 0.5 ml
of methanol (MeOH) by vortexing for 15 min. This solution
was injected into 5 ml of water over the course of approx-
imately 1 s, stirred at 60 rpm, and then rotoevaporated to
remove the MeOH.
75:20:5 D10P:Eudragit RL100:MEH-PPV nanoparticles
were prepared for fluorescent imaging by dissolving 37.5 mg
of D10P and 12.5 mg of Eudragit RL100 in 5 ml of tetra-
hydrofuran (THF) in which 2.5 mg of MEH-PPV was dis-
solved. This solution was injected into 50 ml of water. The
solution was rotoevaporated to remove THF, leaving 8 ml
of suspension. The suspension was then filtered through a 1-

































DS = 1.9 (propionate)
DS = 0.23 (succinate)
D20AQA-TR
Degree of substitution  (DS) = 2.5 (acetate)
and 0.15 (quaternary amine)
D20P-Vivotag
DS = 2.7 (propionate)
D10P
DS = 2.4 (propionate) 
Fig. 2 Structures of dextran
derivatives. DS is the degree of
substitution and refers to the
average number of hydroxyls per
saccharide monomer substituted.




75:20:5 D10P:Eudragit RL100:MEH-PPV Fluorescence imaging
70:25:5 ethyl cellulose:Eudragit RL100:MEH-PPV Viscosity, membrane
dissolution
71:24:5 D10P:Eudragit RL100:MEH-PPV Syringe-filter dissolution
74:21:5 ethyl cellulose:PCL-PEO:MEH-PPV Syringe-filter dissolution
(control)
74:25: 1 ethyl cellulose:PCL-PEO:MEH-PPV Membrane dissolution
(control)
D10PS-RFK-FITC Hydrolytic release
37.5:37.5:25 D10P:D20P-VivoTag:Eudragit RL100 In vivo retention
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70:25:5 ethyl cellulose:Eudragit RL100:MEH-PPV
nanoparticles were prepared for the viscosity and mem-
brane dissolution tests by dissolving 350 mg of ethyl cellu-
lose, 125 mg of Eudragit RL100, and 25 mg of MEH-PPV
in 5 ml of methylene chloride. This solution was then mixed
with 20 ml of Milli-Q water using a rotor stator (Polytron
3100, Kinematica Inc., Bohemia, NY) at 10,000 rpm for
3 min. This coarse emulsion was further emulsified at
12,500 psi for 6 min using a Microfluidizer M110S (Micro-
fluidics, Newton, MA) fitted with a Z-shaped interaction
chamber with a 100-μm-diameter channel. The emulsion
was then placed on a rotoevaporator, where the methylene
chloride was removed under reduced pressure at approxi-
mately 25°C. The resulting aqueous suspension was filtered
through a 1-μm glass-microfiber syringe filter.
Methods similar to those used for the 75:20:5 D10P:
Eudragit RL100:MEH-PPV nanoparticles were used to
prepare the 74:21:5 ethyl cellulose:PCL-PEO:MEH-PPV
and 71:24:5 D10P:Eudragit:MEH-PPV nanoparticles for
the syringe-filter dissolution test and the 74:25:1 ethyl cellu-
lose:PCL-PEO:MEH-PPV nanoparticles for the membrane
dissolution test.
D10PS-RFK-FITC nanoparticles were prepared for
hydrolytic release studies using methods similar to those
used for the D20AQA-TR nanoparticles. 37.5:37.5:25
D20P-VivoTag:D10P:Eudragit RL100 nanoparticles were
prepared by dissolving 22.5 mg of D20P-VivoTag in 1.2 ml
of methylene chloride and then passing the solution through a
0.2-μm filter. Eudragit RL100 (15 mg) and D10P (22.5 mg)
were then dissolved in this solution. Manipulation of the
methylene chloride solution in open vessels was limited in
order to minimize evaporation of the solvent. Water (6.2 ml)
was added to this solution and nanoparticles were made by
emulsification and filtered as described above.
Nanoparticle size was measured by dynamic light scat-
tering (DLS) using a BI-200SM size analyzer with a
BI-9000AT correlator (Brookhaven Instruments Corp.,
Long Island, NY). Nanoparticle size is reported as the
effective hydrodynamic diameter determined using the
cumulant cubic algorithm.
Fluorescence Microscopy
Fluorescence microscopy was performed to visualize the
cross-linked hydrogel formed by cationic nanoparticles and
human OA synovial fluid. D20AQA-TR and 75:20:5 D10P:
Eudragit RL100:MEH-PPV nanoparticle suspensions
(0.2 ml of 3.5 mg/ml in ‘1X’ PBS, pH 7.4), were added
separately to 0.4 ml of human OA synovial fluid, gently
mixed, then spread on glass slides and imaged by fluores-
cence microscopy (Nikon Eclipse E600 optical microscope,
equipped with an ultraviolet–visible [UV/vis] lamp and
Nikon epifluorescence filter block set).
Viscosity Measurement (With and Without Gel)
A cone-and-plate rheometer (TA Instruments AR1000,
New Castle, DE) was calibrated with mineral oil (Viscosity
N75, Catalog No. 9727-C41) (Cannon Instrument Com-
pany, State College, PA) and water. Measurements were
made using a 6-cm-diameter steel flat disk with a gap of
200 μm at 37°C. For these tests, 1 ml of human OA synovial
fluid was mixed with 0.25 ml water and placed on the disk.
Shear stress was measured using a shear rate from 0.1 to
100 Pa. The test was repeated by mixing 1 ml of human OA
synovial fluid with 0.25 ml of a 21.5-mg/ml solution con-
taining 70:25:5 ethyl cellulose:Eudragit RL100:MEH-PPV
nanoparticles.
In Vitro Syringe-Filter Dissolution Test for Convective Transport
(Charged Versus Neutral Nanoparticles)
The ability of convective fluid transport to dislodge nano-
particles from the gel formed between the nanoparticles and
the hyaluronate in synovial fluid was assessed in vitro using a
syringe-filter dissolution test. Two types of nanoparticles
were tested: 74:21:5 ethyl cellulose:PCL-PEO:MEH-
PPV nanoparticles and 71:24:5 D10P:Eudragit RL100:
MEH-PPV nanoparticles. For these tests, 0.33 ml of a 5-
mg/ml nanoparticle suspension was mixed with 0.66 ml of
human OA synovial fluid inside a glass syringe fitted with a
1-μm glass-fiber filter prefilled with 1 ml of human OA
synovial fluid. A syringe pump was used to deliver the
mixture at 0.04 ml/cm2/h through the filter. Fractions
(0.2 ml each) were collected every hour for 7 h. Air was
introduced into the syringe to facilitate initial mixing upon
inversion of the syringe and to aid in expelling the fluid
residing in the filter for the last few timepoints, when the
syringe itself was empty. Nanoparticle transport through the
filter was measured by fluorescence using a Spectramax
M5e plate reader (Molecular Devices, Sunnyvale, CA). An
excitation wavelength of 480 nm was used. Emissions were
collected from 510 to 670 nm in 10-nm increments.
In Vitro Membrane Dissolution Test for Diffusive Transport
(Eudragit Versus PCL-PEO)
The diffusive transport of nanoparticles from human OA
synovial fluid through a semipermeable membrane was
measured in an attempt to assess the potential for transport
across the semipermeable synovial lining of the knee. This
test employed a custom membrane apparatus that has been
previously described (30). Briefly, in this apparatus, two
compartments were separated by a polypropylene mem-
brane with a pore size of 1 μm. On the donor side of the
membrane apparatus, 2 ml of a 20-mg/ml nanoparticle
suspension was combined with 4 ml of human OA synovial
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fluid. The cell was gently shaken briefly to mix. Water (6 ml)
was placed in the receptor side of the apparatus. The appa-
ratus was placed in a temperature-controlled box at 37°C.
Both the donor and receptor media were stirred at 60 rpm.
After 1 h, the cells were placed in sealed jars to eliminate
evaporation. Aliquots of the receptor solution (230 μl each)
were taken at several timepoints and the nanoparticle con-
centration was measured by fluorescence emission using a
plate reader. An excitation wavelength of 480 nm was used.
The fluorescence spectrum of the receptor solution was
collected from 530 to 630 nm, and fluorescence at 590 nm
was plotted. The test was performed for two types of nano-
particles: 70:25:5 ethyl cellulose:Eudragit RL100:MEH-
PPV and 74:25:1 ethyl cellulose:PCL-PEO:MEH-PPV
nanoparticles.
In Vitro Release Test of Fluorescently Tagged Peptide
A solution containing approximately 1 mg/ml of D10PS-
RFK-FITC nanoparticles in PBS (Invitrogen “5X,” [i.e.,
“10X” diluted by a factor of 2]) was placed in an amber glass
vial covered with aluminum foil inside a temperature-
controlled box at 37°C and stirred at 60 rpm. Periodically,
100 μl aliquots were removed and mixed with 100 μl of
MeOH. The RFK-FITC concentration of the sample (i.e.,
the concentration of the fluorescent tag) was analyzed using
a Hewlett Packard Series 1100 high-performance liquid
chromatography (HPLC) instrument (HP Development
Corp., Palo Alto, CA) with a Phenomenex C18 column
(300 Å, 250 mm by 4.6 mm). The following conditions were
used: injection volume of 20 μl, column temperature of
20°C, and flow rate of 1.2 ml/min, with ultraviolet (UV)
detection at 440 nm. A gradient method was used with the
following ratios of Mobile Phase A to Mobile Phase B:
80:20, 48:52, and 0:100 at 0, 24, and 24.5 min, respec-
tively, where Mobile Phase A was 0.1% tetrafluoroacetic
acid (TFA) in water and Mobile Phase B was 0.1% TFA in
acetonitrile (ACN).
The concentration of RFK-FITC released was deter-
mined by comparing results to that of a control solution
with 100% hydrolysis, achieved by adding 1 ml of the 1-mg/
ml nanoparticle suspension to 15 ml of 1 M NaOH (pH
11.5) and stirring overnight.
In Vivo Fluorescence Molecular Tomography (FMT)
The in vivo retention profile of the nanoparticle suspension was
examined in the knee joints of 350-g female Sprague-
Dawley® rats (Charles River Laboratories International
Inc., Wilmington, MA). The animals were anesthetized with
3% isoflurane gas delivered by a laboratory animal anesthesia
system (LAAS) (BioNimbus Inc., Fort Collins, CO). The knee
region was shaved and disinfected with iodine solution and a
90% ethanol scrub. In the control group, 20 μL of VivoTag-
labeled peptide (10mg/ml) was injected into the right knee. In
two separate test groups of animals, 10 μL of 10 mg/ml
37.5:37.5:25 D20P-VivoTag:D10P:Eudragit RL100 linked
peptide was injected intra-articularly, followed by injection
of 10 μL of either PBS or 2 mg/ml hyaluronic acid (n04
animals/group). The purpose of this dual-injection protocol
was to assess whether the addition of extra hyaluronate (in
addition to the endogenous level in the knee) would result in
additional cross-linking and increased retention time. At des-
ignated timepoints up to 1 week, two animals from each group
were sacrificed, and the intact knees were harvested. The skin
of the knees was removed, and the samples were scanned with
a VisEn FMT system to measure the fluorescence level (VisEn
Medical Inc., Woburn, MA). All animal experiments were
approved by the Pfizer Institutional Animal Care and Use
Committee (IACUC) and met all regulatory guidelines.
RESULTS
Nanoparticle Particle-Size Distribution
Nanoparticle size was determined using DLS. Effective
diameters of all nanoparticles, as determined by cubic
cumulant fits, were between 100 nm and 150 nm, with
polydispersities ranging from 0.1 to 0.4. Figure 3 shows
the particle-size distribution for the 37.5:37.5:25 D10P:
D20P-VivoTag:Eudragit RL100 nanoparticle suspension
used in the in vivo retention study. The zeta potential of the
nanoparticles described here was not measured, but the
authors have previously confirmed the expected positive



















Fig. 3 Particle-size distribution for 37.5:37.5:25 D10P:D20P-VivoTag:
Eudragit RL100 nanoparticles that were dosed for in vivo retention studies.
Scattering intensity frequency is plotted, as determined by a CONTIN
fitting algorithm.
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Fluorescence Microscopy
Fluorescence microscopy was used to visualize the mor-
phology of the in situ gels formed after mixing the
fluorescently labeled cationic nanoparticles with human
OA synovial fluid. Figure 4a and b show optical micro-
graphs of gels produced by mixing 75:20:5 D10P:Eudra-
git RL100:MEH-PPV nanoparticles and D20AQA-TR
(i.e., dextran-based) nanoparticles with human OA syno-
vial fluid.
Immediately upon mixing, a discontinuous, filamentous
fluorescent gel formed in the human OA synovial fluid for
both types of cationic nanoparticles. Similar structures
formed when the same nanoparticles were mixed with sol-
utions of hyaluronate (data not shown).
Viscosity of Human OA Synovial Fluid
The effect of cationic nanoparticles on the viscosity of
human synovial fluid was measured as a function of shear
rate to determine if in situ formation of the hydrogel fila-
ments altered the viscoelastic properties of the synovial fluid.
This is an important consideration, because significant alter-
ation of the rheological properties of the synovial fluid could
adversely affect the function of the joint.
Figure 5 shows dynamic viscosity as a function of shear
stress at 37°C for human OA synovial fluid alone and
treated with cationic 70:25:5: ethyl cellulose:Eudragit
RL100:MEH-PPV nanoparticles. The formation of a gel
with the cationic Eudragit-based nanoparticles increased
the measured viscosity of the synovial fluid between 10%
and 40%, depending on the shear stress.
Syringe-Filter Test
To assess whether the in situ formation of hydrogels slowed
transport of the cationic nanoparticles across semipermeable
membranes relative to similar nanoparticles that did not form
the hydrogels, in vitro diffusion and forced convection tests
were performed. Gels were formed by mixing cationic nano-
particles with human OA synovial fluid, and convective trans-
port of the nanoparticles through a membrane was measured
using a syringe filter with a 1-μm filter size, as described in the
Materials and Methods section.
Figure 6 shows a plot of the fluorescence at 580 nm
of the filtrate in the syringe-filter test for two types of
fluorescent nanoparticles in human OA synovial fluid:
(1) cationic 71:24:5 D10P:Eudragit RL100:MEH-PPV
nanoparticles and (2) uncharged 74:21:5:ethyl cellulose:
PCL-PEO:MEH-PPV nanoparticles. As in other tests,
the cationic nanoparticles formed a hydrogel upon mix-
ing, whereas the neutral nanoparticles did not.
The uncharged PCL-PEO nanoparticles quickly passed
through the filter, with the concentration of fluorescence in
the filtrate increasing over the first several hours until it was
equal to the starting concentration in the donormedium at the
4-hour timepoint. In contrast, few of the cationic Eudragit
nanoparticles were forced through the filter by convective
flow. At 7 h, the concentration of cationic nanoparticles in the
filtrate was <0.1% of the concentration in the donor medium.
Membrane Dissolution Test
Since both convective and diffusive transport are likely to
influence nanoparticle clearance from the joint in vivo, the
ability of the ionically cross-linked hydrogel to slow diffusive
transport through a semipermeable synovial membrane was
also measured in vitro.
Diffusive transport of nanoparticles in human OA syno-
vial fluid was measured in vitro using a semipermeable poly-
propylene membrane with a 1-μm pore size, as described in
the Materials and Methods section. Figure 7 shows the
percentage of nanoparticles transported through the mem-
brane as a function of time for fluorescent nanoparticles
similar to those tested in the syringe-filter test: cationic
71:24:5 D10P:Eudragit RL100:MEH-PPV nanoparticles
and uncharged 74:21:5:ethyl cellulose:PCL-PEO:MEH-
PPV nanoparticles. Again, transport was determined by
fluorescence of the receptor solution at 580 nm. As shown
in Fig. 7, the transport of the uncharged PCL-PEO nano-
particles was three orders of magnitude higher than for the
cationic Eudragit nanoparticles over the course of the 7-h
experiment. The concentration of the uncharged nanoparticles
essentially equilibrated between the donor and receptor media
Fig. 4 Fluorescent microscopic
images of gelled 75:20:5 D10P:
Eudragit RL100:MEH-PPV
nanoparticles (a) and D20AQA-
TR (i.e., dextran-based) nanopar-
ticles (b) with human OA synovial
fluid.
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within 2 h, whereas less than 0.1% of the charged nanopar-
ticles passed through the membrane during the 7-h test.
Hydrolysis of Peptide from Polymer
An in vitro release study was performed to assess whether
acceptable in vivo release rates of small molecules are likely to
be achieved from the nanoparticles using hydrolyzable ester
bonds. Using an ester linkage, a short fluorescent peptide
consisting of three amino acids (i.e., RFK) was conjugated to
a hydrophobically derivatized dextran polymer typical of those
used in the core of the cationic nanoparticles. The hydrolytic
release of the peptide was measured in vitro under physiological
pH and temperature to assess the likely release rate in vivo.
Figure 7 shows the in vitro release of the peptide from the
D10PS-RFK-FITC polymer via ester hydrolysis at 37°C and
pH 7.4. As shown in Fig. 8, approximately 20% of the RFK
peptide was released over 147 h (~6 days), with a roughly
linear release rate, demonstrating that the nanoparticles can
release a small molecule at a sustained rate over an extended
period.
In Vivo Retention in Rats
The retention of fluorescent 37.5:37.5:25 D10P:D20P-Viv-
oTag:Eudragit RL100 nanoparticles within the knee joint
after intra-articular injection in rats was measured using
FMT. The animals did not show any adverse effects, such
as signs of pain or inflammation, after intra-articular injec-
tion. Figure 9 summarizes the retention data for
37.5:37.5:25 D10P:D20P-VivoTag:Eudragit RL100 nano-
particles versus a fluorescently tagged free tetrapeptide.
When the fluorescently labeled free tetrapeptide was
injected intra-articularly, the fluorescence levels decreased
to 23% of the initial concentration within 2 days. In con-
trast, 74% of the fluorescent tag incorporated into the nano-
particles via an ester bond remained in the knee 7 days after
injection.
To determine if the endogenous level of hyaluronate in
the knee joint was sufficient to form ionically cross-linked
















Human OA synovial fluid + 
cationic nanoparticles
Fig. 5 Viscosity as a function of shear stress of human OA synovial fluid





























Fig. 6 Forced convective transport of fluorescent nanoparticles in humanOA
synovial fluid through a 1-μm syringe filter: cationic 71:24:5 D10P:Eudragit
RL100:MEH-PPV nanoparticles and uncharged 74:21:5:ethyl cellulose:PCL-






































Fig. 7 Diffusive transport of fluorescent nanoparticles in human OA
synovial fluid through a semipermeable 1-μm membrane: cationic

















Fig. 8 Hydrolysis of RFK peptide from D10PS-RFK-FITC nanoparticles
over time.
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(n04) was given an intra-articular injection of exogenous
hyaluronic acid immediately following the nanoparticle
injection. The dynamic profile of fluorescence signal
changes in the knees of these animals was very similar to
those of the animals that did not receive the exogenous
hyaluronate (Fig. 8). This suggests that the endogenous level
of hyaluronate is adequate to bind the entire dose of nano-
particles ionically.
DISCUSSION
The goal of this study was to demonstrate the feasibility of
using active compounds covalently attached to cationic
nanoparticles to extend intra-articular retention time and
prolong release of active small molecules.
In these studies, several nanoparticle formulations were
made and characterized using in vitro methods. The nano-
particles were generally composed of a cationic polymer and
at least one uncharged polymer. The nanoparticles described
here were made by either an emulsion/evaporation method
or by precipitation from solvent/nonsolvent mixing. They are
believed to form core/shell structures in which the charged
polymer predominantly resides on the surface of the nano-
particle and the neutral polymer(s) preferentially reside inside
the core of the nanoparticle. This arrangement is plausible
based on the more hydrophilic nature of the charged polymer
relative to that of the uncharged polymers. In addition, the
interaction observed between the nanoparticles and the
anionic hyaluronate suggests a significant fraction of the cat-
ionic charge lies on the surface of the nanoparticle. Finally, the
core/shell structure is consistent with x-ray photoelectron
spectroscopy (XPS) surface analysis performed by the authors
on dried nanoparticles having a composition similar to those
described in these studies.
The results from these studies show that discontinuous,
filamentous structures are formed when nanoparticles based
on Eudragit RL100 or cationically modified dextran are
added to whole human OA synovial fluid. The structures
are believed to be ionically cross-linked materials consisting
of cationic nanoparticles and anionic hyaluronate. Based on
their appearance and on the water-swollen nature of hya-
luronate, the filaments likely comprise a hydrogel, which
forms a separate (discontinuous) phase in the synovial fluid
(continuous phase). At sufficiently high concentrations of
hyaluronate and cationic nanoparticles, the materials might
form a single hydrogel phase.
Given the substantial structural differences between
Eudragit RL100 and the cationic dextran tested, there is
likely great latitude in the choice of cationic polymers.
Modified dextrans are likely preferable to Eudragit
RL100, since the substituted dextrans are biodegradable
and form water-soluble products (e.g., dextran and pro-
pionic acid from dextran propionate), which can be cleared
from the body through the kidneys. In addition, initial
unpublished data of the authors suggests that intravenous
injection of nanoparticles composed of uncharged ester-
modified dextrans are well tolerated by rodents, although
select anionic nanoparticles appear to be less so when
administered systemically. More work is necessary to assess
the safety of various derivatized dextrans when administered
by different routes.
Like the cationic polymer, the uncharged core polymer can
be varied while enabling effective gel formation by the cationic
surface polymer. Different core polymers—D10P and ethyl
cellulose—were used in the in vitro syringe-filter and mem-
brane dissolution tests, respectively, and both resulted in the
formation of the ionic gel by the cationic surface polymer.
The results described above suggest that selection of the
surface and core polymers can be tailored to maximize
safety without adversely affecting an ionic association or
cross-linking needed to achieve nanoparticle retention
within the targeted tissue.
The rheological testing results using human OA synovial
fluid are promising, in that the viscosity of the synovial fluid
was not drastically affected by the formation of the filamen-
tous cross-linked hydrogel, being 40% more viscous at the
lowest shear stress measured (0.1 Pa) and only 10% more
viscous at higher shear stresses. In this testing, an attempt
was made to use a nanoparticle suspension with a concen-
tration and volume relative to the synovial fluid that is
relevant for drug-delivery applications. Since the viscosity
of the synovial fluid is mainly attributable to hyaluronate, it
is encouraging that the viscosity of the synovial fluid did not
increase much with addition of nanoparticles. This could be
because the ionically associated material is not very strongly
linked and/or that it forms a second, discontinuous phase in
the synovial-fluid continuous phase and, thus, does not have
a large impact on the rheological properties of the continu-
ous phase. The result suggests that binding of a portion of
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Fig. 9 In vivo pharmacokinetics of 37.5:37.5:25 D10P:D20P-VivoTag:
Eudragit RL100 nanoparticles coinjected with PBS or hyaluronate versus
free tetrapeptide in PBS.
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the hyaluronate with the nanoparticles is not likely to
adversely affect the important rheological functions of hya-
luronate in the joint and, therefore, that the injection of a
therapeutic agent using these cationic nanoparticles would
not damage the knee joint by drastically changing the lubri-
cation properties and other characteristics of the fluid in the
joint. Likewise, the small size of the nanoparticles (~130 nm)
and the diffuse, compliant nature of the cross-linked gel are
not likely to cause cartilage damage or other mechanical
damage in the joint.
The syringe-filter and membrane dissolution tests were
used to measure convective and diffusional transport,
respectively, of the charged nanoparticles, respectively, out
of the ionically cross-linked hydrogel. Both types of trans-
port are likely to be relevant for the elimination of thera-
peutic agents and their associated vehicles from the knee
joints in vivo. In this study, the effect of the biomechanics of
the knee—e.g., the pressure in the synovial cavity due to
movement—on these two types of transport was not
addressed. Further investigation of these effects will be pur-
sued as part of future work.
The 1-μm pore size used in convective and diffusional
transport tests was selected to approximate the size of the
intercellular gaps reported for the synovial membrane
surrounding the synovial cavity (31,32). This is likely an
overestimate of the effective pore size, as macromolecular
transport across the membrane suggests much smaller
effective pore sizes—diameters of 66 to 118 nm for
hyaluronidase (33) and 174 nm for dextran (34). From the
optical microscopy images, the size of the gel filaments
appeared to be many microns and, therefore, would not
be expected to pass throught the 1-μm filter, although the
~100- to150-nm nanoparticles would be expected to pass
through the filter if they were free in suspension and not
incorporated into the gel.
The flow rate chosen for the in vitro convection studies
(0.04 ml/cm2/hr) was approximately 20 times that reported
for synovial fluid in the knee (35). It was chosen to determine if
the gel could remain intact under the maximum anticipated
physiological convective forces observed/measured in the
joint. The 2-h time lag for transport of the neutral nano-
particles is due to limited mixing of the nanoparticle suspen-
sion with the synovial fluid that was prefilled into the syringe
filter and expelled during the collection of aliquots at the
initial timepoints. The higher concentration of fluorescence
in the receptor solution relative to the donor suspension
(150% of the initial concentration in the donor suspension) is
likely due to incomplete mixing of the nanoparticles in the
synovial fluid, resulting in inhomogeneity in the donor
suspension. Some inhomogeneity was likely present because
the viscous donor suspension was only gently mixed prior to
the test to avoid shear-induced cleavage of the hyaluronate
that might result from more vigorous mixing.
Dextran was chosen as the polymeric platform for this set
of studies because of its long safety record as a blood plasma
expander. Dextrans of up to 70 kDa are routinely used for
that application and are degraded and cleared from the
body safely. The dextran was derivatized as the propionate
ester to render it insoluble for the production of nanopar-
ticles while maintaining the biodegradability of the polymer
through hydrolysis and esterase pathways. The esterification
of the dextran with functional substituents has proven to be
straightforward, which allows the polymer properties to be
adjusted for optimum performance and safety.
The rate of release of a short peptide conjugated to the
nanoparticles via ester hydrolysis was approximately 20%
over 6 days, which is appropriate for providing approximately
1-month duration of exposure of a therapeutic agent after
injection into the knee cavity, assuming a similar rate in vivo.
The ester hydrolysis rate measured was similar to rates for
similar esters reported in the literature. For example, Larsen
reported half lives of between 280 and 312 h in human OA
synovial fluid for a naproxen prodrug formed from dextran
backbones (36). Ester hydrolysis of a succinate group linked to
the n-terminus is ideal for this particular peptide, and this
approach is likely applicable to a wide range of active mole-
cules. For nonpeptide small active compounds, alternate con-
jugation chemistries can be tailored to the chemical structure
to achieve the desired release profile. For large mole-
cules, including proteins, noncovalent incorporation into nano-
particles can be used, for example by using polyionic interactions
between the protein and the synthetic polymer used in the
nanoparticle carrier.
The in vivo examination of the cationic nanoparticles dem-
onstrated that exogenously injected hyaluronate was not nec-
essary to increase the retention time. The result suggests that
the concentration of endogenous hyaluronate in the synovial
fluid is sufficient for association to the nanoparticles and for
slowing their otherwise rapid transport out of the synovium.
The FMT signal is due to the ester-linked fluorophore.
Therefore, in the current study, fluorescent signal in the knee
is lost when either the nanoparticles themselves are trans-
ported out of the joint or when the fluorophore is released
from the nanoparticles by hydrolysis and exits the joint, leav-
ing the nanoparticles behind. The latter mechanism is pre-
ferred for sustained drug-delivery applications, so that the
drug is released within the joint rather than after exiting the
joint with the nanoparticles. Determining the extent to which
the decrease in fluorescence in the knee is due to transport of
hydrolyzed free fluorescent peptide versus transport of peptide
in nanoparticles would require additional experiments that
were beyond the scope of this study. However, because the
loss of fluorescence in the knee in vivo closely matched the in
vitro ester hydrolysis rate of approximately 20% per week,
most of the signal decrease observed over the 1-week in vivo
study was likely due to transport of fluorophore out of the joint
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after hydrolysis from the nanoparticles, rather than from
transport of intact nanoparticles themselves out of the joint.
This question will be addressed in future studies in which the
nanoparticles and modeled drug will be labeled separately.
Future work will focus on testing the described nano-
particle formulations with known DMOADs (e.g., MMP-
13 and aggrecanase small-molecule inhibitors) to determine
the effectiveness of this approach in blocking cartilage deg-
radation and bone erosion in various animal models of OA.
CONCLUSIONS
The feasibility of using cationic nanoparticles to increase the
retention time of drugs in the knee joint of rats has been
demonstrated, offering a new promising approach for
achieving increased retention and sustained delivery of
drugs in the knee cavity for treatment of OA or other
rheumatic diseases. This platform would enable less fre-
quent injections, decreasing both cost and patient discom-
fort, while potentially increasing the effectiveness of
treatments by providing a more stable drug concentration.
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